ArticleAmerican journal of respiratory cell and molecular biology2016
Molecular Analysis of Sarcoidosis Granulomas Reveals Antimicrobial Targets.
Article in American journal of respiratory cell and molecular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Diagnosis and treatment of sarcoidosis based on immunological etiology and mechanisms.Frontiers in medicine · 2026Review
- Sarcoidosis: molecular mechanisms and therapeutic strategies.Molecular biomedicine · 2025Review
- Cellular Recycling Gone Wrong: The Role of Dysregulated Autophagy and Hyperactive mTORC1 in the Pathogenesis of Sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis.International journal of molecular sciences · 2023Review
- Sarcoidosis rates in BCG-vaccinated and unvaccinated young adults: A natural experiment using Danish registers.Seminars in arthritis and rheumatism · 2023Article
- Circulating Regulatory T Cell Subsets in Patients with Sarcoidosis.Diagnostics (Basel, Switzerland) · 2023Article
- Granulomatous inflammation in inborn errors of immunity.Frontiers in pediatrics · 2023Review
- The Role ofMicroorganisms · 2022Review
- Systemic immune response to vimentin and granuloma formation in a model of pulmonary sarcoidosis.Journal of translational autoimmunity · 2022Article
- Immunohistochemical Detection ofMicroorganisms · 2021Article
- A Primer on the Clinical Aspects of Sarcoidosis for the Basic and Translational Scientist.Journal of clinical medicine · 2021Review
- The Great Italian Masquerade.Journal of community hospital internal medicine perspectives · 2021Article
- Immunohistochemical Detection of Potential Microbial Antigens in Granulomas in the Diagnosis of Sarcoidosis.Journal of clinical medicine · 2021Review
- Are infectious diseases risk factors for sarcoidosis or a result of reverse causation? Findings from a population-based nested case-control study.European journal of epidemiology · 2020Article
- Key Players and Biomarkers of the Adaptive Immune System in the Pathogenesis of Sarcoidosis.International journal of molecular sciences · 2020Review
- Environmental Risk Factors for Sarcoidosis.Frontiers in immunology · 2020Review
- Environment, Epigenetics, and Differential Responses to Beryllium Exposure: Are We There Yet?American journal of respiratory cell and molecular biology · 2019Article
- Potential immunotherapies for sarcoidosis.Expert opinion on biological therapy · 2018Review
- Review
- Programmed Death-1 Inhibition of Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target of Rapamycin Signaling Impairs Sarcoidosis CD4American journal of respiratory cell and molecular biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Sarcoidosis is a granulomatous disease of unknown cause. Prior molecular and immunologic studies have confirmed the presence of mycobacterial virulence factors, such as catalase peroxidase and superoxide dismutase A, within sarcoidosis granulomas. Molecular analysis of granulomas can identify targets of known antibiotics classes. Currently, major antibiotics are directed against DNA synthesis, protein synthesis, and cell wall formation. We conducted molecular analysis of 40 sarcoidosis diagnostic specimens and compared them with 33 disease control specimens for the presence of mycobacterial genes that encode antibiotic targets. We assessed for genes involved in DNA synthesis (DNA gyrase A [gyrA] and DNA gyrase B), protein synthesis (RNA polymerase subunit β), cell wall synthesis (embCAB operon and enoyl reductase), and catalase peroxidase. Immunohistochemical analysis was conducted to investigate the locale of mycobacterial genes such as gyrA within 12 sarcoidosis specimens and 12 disease controls. Mycobacterial DNA was detected in 33 of 39 sarcoidosis specimens by quantitative real-time polymerase chain reaction compared with 2 of 30 disease control specimens (P < 0.001, two-tailed Fisher's test). Twenty of 39 were positive for three or more mycobacterial genes, compared with 1 of 30 control specimens (P < 0.001, two-tailed Fisher's test). Immunohistochemistry analysis localized mycobacterial gyrA nucleic acids to sites of granuloma formation in 9 of 12 sarcoidosis specimens compared with 1 of 12 disease controls (P < 0.01). Microbial genes encoding enzymes that can be targeted by currently available antimycobacterial antibiotics are present in sarcoidosis specimens and localize to sites of granulomatous inflammation. Use of antimicrobials directed against target enzymes may be an innovative treatment alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.